地诺单抗中文说明书

Basically all solid tumors may have bone metastasis, such as breast cancer, prostate cancer, lung cancer, thyroid cancer, kidney cancer, gastrointestinal cancer, etc. Cancer cells that have metastasized to the bone can secrete a substance that causes osteoclasts to "eat" bone material. The incidence of bone metastasis in breast cancer and prostate cancer is as high as more than 70%, and data reports on lung cancer vary, with some being as high as 85%. Currently, the bone metastasis drug commonly used in China is zoledronic acid, and multiple clinical studies have shown that it is significantly more effective than zoledronic acid in patients with bone metastasis from solid tumors. Next, we will bring you the Chinese instructions for denosumab.

[Drug name] Denosumab

【Product name】Xgeva

[Specification] 120mg/1.7ml; solution

[Recommended Usage and Dosage] (1) Xgeva can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

[Storage] Store in the refrigerator at 2-8°C in the original box. Do not freeze, once removed from the refrigerator, do not expose to temperatures above 25°C or light, must be used within 14 days.

[Adverse Reactions] (1) The most common adverse reactions (≥25%) in patients with solid tumor bone metastases are fatigue/asthenia, hypophosphatemia and nausea. (2) Common adverse reactions (≥10%) in patients with giant cell tumor of bone include headache, joint pain, nausea, back pain, fatigue and limb pain. (3) Adverse reactions of malignant hypercalcemia (≥20%) include nausea and vomiting, dyspnea, loss of appetite, headache, peripheral edema, anemia, diarrhea and constipation.

Summary: Bone metastasis is an unavoidable disease outcome for many cancer patients in the late stage, especially breast cancer, prostate cancer and lung cancer. For patients with bone metastases, there are better treatment advantages.